Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study makes progress in zoning in on biomarkers for better colon cancer treatment

26.09.2007
New research has yielded a clearer picture of which biomarkers could help doctors more precisely target the treatment of colon cancer, bringing closer the day when patients who will not benefit from chemotherapy are spared it, while those that will, get the more aggressive treatment they need.

As with many other solid tumours, doctors plan treatment of colon cancer chiefly by staging the tumour, which involves assessing how deep it has infiltrated into the bowel wall and how far the cancer has spread. Generally, if the cancer has spread to the lymph nodes, chemotherapy is given after surgery to prevent recurrence.

“That approach is not very precise,” said the study’s lead investigator, Dr Arnaud Roth, a medical oncologist and chief of Oncosurgery at the University Hospital of Geneva, Switzerland. “Even if the lymph nodes are involved, at least half of those patients won’t ever suffer a relapse and could be spared chemotherapy. However, since there is no good tool to distinguish them from the people who have a high likelihood of relapse, all patients with cancer detected in lymph nodes are treated with chemotherapy.

“New tools are needed to make this distinction and biomarkers are one possibility,” said Roth, who presented a large study on this subject today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona.

... more about:
»Treatment »chemotherapy »colon

Since the decoding of the human genome, scientists have increasingly been looking for genes or protein biomarkers consistently over-expressed or under-expressed in cancer tissue to see if those markers can help better determine prognosis and tailor treatment for individual patients.

The study, by a team of European scientists which Roth coordinates, examines in one of the largest patient groups to date a broad panel of candidate biomarkers suspected of playing a role in colon cancer.

“The results are preliminary but extremely encouraging. This study will, we hope, clarify which biomarkers will be clinically useful, which are probably not and which will have the most impact. There have been a lot of studies of limited scope previously, but nothing conclusive,” Roth said.

The researchers examined potentially promising biomarkers in 1,564 samples, preserved as part of a chemotherapy study, of healthy and cancerous colon tissue from patients operated on in more than 368 hospitals in Europe. More than 10 molecular markers were investigated with a high success rate (>90%), demonstrating the method’s feasibility with routinely processed tissue.

“If one of those markers is strongly linked to the reaction to chemotherapy, it might be useful to test in a clinical trial its value in deciding whether to give chemotherapy or not,” Roth said.

“For instance, it’s early in our analysis, but SMAD4 is looking quite good, in that patients with high SMAD4 expression had a significantly better prognosis than those with low expression. It would have to be investigated further, but maybe patients who strongly express the SMAD4 gene don’t need any additional therapy after surgery.

“On the other hand, in this patient population with adjuvant therapy, we found that KRAS, a type of gene called an oncogene that is involved in regulating cell division, has no prognostic value whatsoever – zero. So we think KRAS can be abandoned as a potential prognostic biomarker for colon cancer,” Roth added.

The study was supported by Pfizer Inc.

Catalogue no: 3013, Wednesday 09.00 hrs CET (Room 110)

Emma Ross | alfa
Further information:
http://www.ecco-org.eu/News/News/In-the-news/page.aspx/72

Further reports about: Treatment chemotherapy colon

More articles from Life Sciences:

nachricht How brains surrender to sleep
23.06.2017 | IMP - Forschungsinstitut für Molekulare Pathologie GmbH

nachricht A new technique isolates neuronal activity during memory consolidation
22.06.2017 | Spanish National Research Council (CSIC)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>